Tel:4000-996-336 CN

Professor Yan Hai Was Awarded Excellent Professor Prize of Duke University School of Medicine

Release Time: 2018-01-12

Figure: Professor Yan Hai Was Awarded Excellent Professor Prize of Duke University School of Medicine.

Recently, Professor Yan Hai, Chief Scientist of Genetron Health, was awarded the Excellent Professor Prize by Duke University School of Medicine, in recognition of the landmark of his discovery of gene IDH1 / 2 , gene ATRX and TERT   promoter mutation. Such findings are important basis for glioma molecular typing, and have great significance to provide more accurate diagnosis and prognosis information, to promote the achievement of personalized treatment and customized clinical trials, and to re-recognize the occurrence and development of glioma. In addition, just like the other professors of the School of Medicine who have made extraordinary achievements, Professor Yan Hai's portrait will also be hung on the wall of the corridor as the recognition.

As an internationally renowned scholar in oncology genomics and individualized treatment, Professor Yan Hai has been exploring in the field of genetics for more than twenty years. Since 1990, Professor Yan Hai began to engage in molecular biology. In 1997, he studied molecular biology and genomics of colorectal cancer from Professor Bert Vogelstein of Johns Hopkins University, and later studied on brain tumor in Duke University, when his main research area was the discovery, mutation function research and targeted therapy of gene drive in relation to the occurrence and development of cancer.

With the ambition of overcoming cancer, in the vast ocean of genomics, Professor Yan has eventually achieved remarkable results in the field of brain tumors. In 2009, Professor Yan and his team found gene  IDH1 / 2 , which so far has been quoted for more than 2600 times. The related articles were voted as the "Top Articles in the Field of Cancer" by <Natural Medicine>.In 2013, it was found that the TERT <promoter mutation was a key driver of many common tumors, and one of the most important evidences for brain tumor molecular typing had been found following the discovery of IDH1. In addition, a new test program had been provided for the diagnosis and treatment of many other cancers. Besides, Professor Yan is one of the inventors of BEAMing technology. He also invented a method for the separation of the genetic alleles of tumors, and the quantitative determination of relative expression of two alleles.

Having such outstanding contribution in his specialization, Professor Yan won many accreditations. In 2009, he was awarded the Outstanding Scientific Research Prize of Brain Tumor Genome Founder by the American Brain Tumor Fund, the only prize for scientific team by American Society for Cancer Research (AACR) in 2014, and the honorary title of Distinguished and Endowed Professor of Duke University.

"As a researcher, I am proud to be able to independently engage in the cancer genomics research which made me feel zealous for and to make success in the field of my expertise," said Professor Yan. When the discussion came to the brain glioma gene research which he mainly specializes in, Professor Yan has always been very proud with emulative enthusiasm, "We hope our research can bring long-term benefits to the public health and the economic and social development."

With the solid foundation in his professional field and his tireless research spirit, Professor Yan has also made great achievement in academic monographs: He has 97 papers published in SCI, including 5 articles as the first or corresponding author on NEJM, Science and Nature, 5 articles on CNS sub-journal, 18 articles (inclusive of papers, overviews and reviews) on journals with impact factor ≥ 10, and 18 items of application for U.S. patent. It is worth mentioning that in March 2017, Professor Yan was invited to write <Translational Immunotherapy of Brain Tumors> and <The Duke Glioma Handbook>, both of which have been officially published and are expected to provide scientific insights and new ideas for researchers and clinicians.

Figure: Book Cover

To promote the application of scientific research achievements into clinical treatment and benefit more cancer patients in China, Professor Yan Hai returned to China in 2013 and established the company which has the equal international background and focuses on cancer precision medicine — Genetron Health, to be committed to validating the application of cancer genomics, to provide patients with reliable molecular treatment programs and professional cancer-related genetic risk assessment.

Figure: Work Photo of Professor Yan Hai in Genetron Health

In respect of international cooperation, Genetron Health has established a long-term partnership with Duke University and Johns Hopkins University — two of the most prestigious cancer research centers in the United States, enabling us to have the world's leading technical information of cancer research: We have set up in-depth cooperation with Duke University Cancer Genomics Laboratory and the Brain Tumor Research Center, and have established an exclusive strategic partnership with Personal Genomic Diagnostics, a genetic testing company created by Professor Bert Vogelstein of Johns Hopkins University. Also, we have developed cooperation with top-class hospitals and pharmaceutical enterprises in both China and the US on clinical treatment, scientific research and data analysis, thus the testing services and kit products can serve in both Chinese and American markets. In addition, the research team of Genetron Health is composed of experts from world-class universities and research institutions. The team of experts has the academic backgrounds in cancer genetics, cancer genomics, bioinformatics, pharmacology, clinical pathology, and many other fields.